D C Ling1, B V Chapman1, J Kim2, G W Choby2, P Kabolizadeh1, D A Clump1, R L Ferris2, S Kim2, S Beriwal1, D E Heron3, U Duvvuri4. 1. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. 2. Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. 3. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. 4. Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Electronic address: duvvuriu@upmc.edu.
Abstract
OBJECTIVE: It has been postulated that treatment outcomes are similar between transoral robotic surgery (TORS) and definitive chemoradiation (CRT) for oropharyngeal squamous cell carcinomas (OPSCC). We compared oncologic and quality of life (QOL) outcomes between definitive CRT and definitive TORS. MATERIALS AND METHODS: An observational comparison study was performed on 92 patients treated with TORS±adjuvant therapy and 46 patients treated with definitive CRT between July 2005 and January 2016. The Kaplan Meier method was used for survival analyses, and the Mann-Whitney test was used to compare QOL scores between groups. RESULTS: All patients had T0-T2 and N0-N2 disease, although CRT patients had higher clinical staging (p<0.001). HPV+ disease was present in 79% (n=73) of TORS patients and 91% (n=19) of tested CRT patients. Median follow-up was 22.1months (range: 0.33-83.4). There were no significant differences in locoregional control or overall survival between CRT and TORS groups. Definitive TORS resulted in better saliva-related QOL than definitive CRT at 1, 6, 12, and 24months (p<0.001, p=0.025, p=0.017, p=0.011). Among TORS patients, adjuvant therapy was associated with worse QOL in the saliva domain at 6, 12, and 24months (p<0.001, p<0.001, p=0.007), and taste domain at 6 and 12months (p=0.067, p=0.008). CONCLUSION: Definitive CRT and definitive TORS offer similar rates of locoregional control, overall survival, and disease-free survival in patients with early stage OPSCC. TORS resulted in significantly better short and long-term saliva-related QOL, whereas adjuvant therapy was associated with worse saliva and taste-related QOL compared to TORS alone. Published by Elsevier Ltd.
OBJECTIVE: It has been postulated that treatment outcomes are similar between transoral robotic surgery (TORS) and definitive chemoradiation (CRT) for oropharyngeal squamous cell carcinomas (OPSCC). We compared oncologic and quality of life (QOL) outcomes between definitive CRT and definitive TORS. MATERIALS AND METHODS: An observational comparison study was performed on 92 patients treated with TORS±adjuvant therapy and 46 patients treated with definitive CRT between July 2005 and January 2016. The Kaplan Meier method was used for survival analyses, and the Mann-Whitney test was used to compare QOL scores between groups. RESULTS: All patients had T0-T2 and N0-N2 disease, although CRT patients had higher clinical staging (p<0.001). HPV+ disease was present in 79% (n=73) of TORSpatients and 91% (n=19) of tested CRT patients. Median follow-up was 22.1months (range: 0.33-83.4). There were no significant differences in locoregional control or overall survival between CRT and TORS groups. Definitive TORS resulted in better saliva-related QOL than definitive CRT at 1, 6, 12, and 24months (p<0.001, p=0.025, p=0.017, p=0.011). Among TORSpatients, adjuvant therapy was associated with worse QOL in the saliva domain at 6, 12, and 24months (p<0.001, p<0.001, p=0.007), and taste domain at 6 and 12months (p=0.067, p=0.008). CONCLUSION: Definitive CRT and definitive TORS offer similar rates of locoregional control, overall survival, and disease-free survival in patients with early stage OPSCC. TORS resulted in significantly better short and long-term saliva-related QOL, whereas adjuvant therapy was associated with worse saliva and taste-related QOL compared to TORS alone. Published by Elsevier Ltd.
Entities:
Keywords:
Chemoradiotherapy; Head and neck cancer; Oropharyngeal cancer; Quality of life; Robotic surgical procedures; Squamous cell carcinoma; Treatment outcome
Authors: Michael J Persky; William G Albergotti; Tanya J Rath; Mark W Kubik; Shira Abberbock; Mathew Geltzeiler; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris Journal: Otolaryngol Head Neck Surg Date: 2017-11-28 Impact factor: 3.497
Authors: Xu Qian; Branko Sinikovic; Frank Schreiber; Sebastian Ochsenreither; Konrad Klinghammer; Barbara Wollenberg; Andreas M Kaufmann; Andreas E Albers Journal: Eur Arch Otorhinolaryngol Date: 2018-08-29 Impact factor: 2.503
Authors: David J Sher; Abiy Agiro; Siting Zhou; Andrew T Day; Andrea DeVries Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-10-01 Impact factor: 6.223
Authors: Hani Z Marzouki; Vincent L Biron; Peter T Dziegielewski; Andrew Ma; Jason Vaz; Gabriela Constantinescu; Jeffrey Harris; Daniel O'Connell; Hadi Seikaly Journal: J Otolaryngol Head Neck Surg Date: 2018-09-19
Authors: Benjamin H Kann; Sanjay Aneja; Gokoulakrichenane V Loganadane; Jacqueline R Kelly; Stephen M Smith; Roy H Decker; James B Yu; Henry S Park; Wendell G Yarbrough; Ajay Malhotra; Barbara A Burtness; Zain A Husain Journal: Sci Rep Date: 2018-09-19 Impact factor: 4.379
Authors: Han Zhang; Michael Xie; Marc Levin; Stuart D Archibald; B Stanley Jackson; J E M Young; Michael K Gupta Journal: J Otolaryngol Head Neck Surg Date: 2019-09-02